OncoMatch/Clinical Trials/NCT06329869
Sacituzumab Govitecan for Advanced Esophageal Squamous Cell Carcinoma
Is NCT06329869 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Sacituzumab govitecan for esophageal squamous cell carcinoma.
Treatment: Sacituzumab govitecan — The goal of this clinical trial is to investigate the efficacy and safety of sacituzumab govitecan in patients with advanced esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Biomarker criteria
Required: TACSTD2 expression testing required (testing required; no eligibility threshold specified)
Archival tumor tissue for Trop-2 expression and optional fresh biopsy if feasible. No adequate archival or fresh ESCC tumor tissues for characterization of Trop-2 expression [excluded].
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
failed prior platinum-based chemotherapy
Must have received: anti-PD-1 therapy
failed prior ... anti-PD-1/PD-L1 therapy (adjuvant anti-PD-1 therapy considered as prior exposure of anti-PD-1/PD-L1 therapy)
Cannot have received: topoisomerase 1 inhibitor
Have previously received topoisomerase 1 inhibitors
Lab requirements
Blood counts
hemoglobin ≥ 9 g/dL, ANC ≥ 1500/mm3, and platelets ≥ 100,000/µL without transfusional or growth factor support within 2 weeks of study drug initiation
Kidney function
creatinine clearance ≥ 30 mL/min as assessed by the Cockcroft-Gault equation
Liver function
bilirubin ≤ 1.5 x ULN, AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if known liver metastases, and serum albumin > 3 g/dL
Adequate hematologic counts ... Adequate hepatic function ... Creatinine clearance ≥ 30 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify